会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • テトラヒドロピラン化合物の製造方法
    • 生产四氢呋喃化合物的方法
    • WO2007086559A1
    • 2007-08-02
    • PCT/JP2007/051387
    • 2007-01-29
    • 宇部興産株式会社西野 繁栄弘津 健二島 秀好敷田 庄司岩本 圭司原田 崇司
    • 西野 繁栄弘津 健二島 秀好敷田 庄司岩本 圭司原田 崇司
    • C07D309/08C07D309/04C07D309/30
    • C07D309/08
    • Disclosed is a method for producing a 4-cyanotetrahydropyran-4-carboxylic acid ester represented by the general formula (4a) or (4b) below, which is characterized in that a bis(2-halogenoethyl) ether represented by the general formula (1) below, a cyanoacetic acid ester represented by the general formula (2) below and an alkali metal alkoxide represented by the general formula (3) below are reacted in an organic solvent. (1) (In the formula, X represents a halogen atom.) (2) (In the formula, R 1 represents an alkyl group having 2-6 carbon atoms.) (3) (In the formula, R 2 may be the same as or different from R 1 and represents an alkyl group having 1-6 carbon atoms, and M represents an alkali metal atom.) (4a) (4b) (In the formulae, R 1 and R 2 are as defined above.) Also disclosed is a method for producing 4-cyanotetrahydropyran represented by the formula (5), which is characterized in that at least one 4-cyanotetrahydropyran-4-carboxylic acid ester is reacted in a solvent. Further disclosed is a method for producing tetrahydropyran-4-carboxylic acid amide represented by the general formula (6), which is characterized in that the 4-cyanotetrahydropyran and a base are reacted in a solvent.
    • 公开了由下述通式(4a)或(4b)表示的4-氰基四氢吡喃-4-羧酸酯的制备方法,其特征在于由通式(1)表示的双(2-卤代乙基)醚 ),下述通式(2)表示的氰基乙酸酯和下述通式(3)表示的碱金属醇盐在有机溶剂中反应。 (1)(式中,X表示卤素原子)(2)(式中,R 1表示具有2-6个碳原子的烷基)(3)(在 式R 2可以与R 1相同或不同,并且表示具有1-6个碳原子的烷基,M表示碱金属原子。)( 4a)(4b)(式中,R 1和R 2如上所定义。)还公开了一种由式(4)表示的4-氰基四氢吡喃的制备方法, 5),其特征在于至少一种4-氰基四氢吡喃-4-羧酸酯在溶剂中反应。 进一步公开的是通式(6)表示的四氢吡喃-4-羧酸酰胺的制造方法,其特征在于4-氰基四氢吡喃和碱在溶剂中反应。
    • 8. 发明申请
    • ヒトSGLTホモログプロモーターおよびその用途
    • 人类社会发展促进者及其使用
    • WO2003056005A1
    • 2003-07-10
    • PCT/JP2002/013651
    • 2002-12-26
    • 武田薬品工業株式会社岩本 圭司片山 望河村 美穂子
    • 岩本 圭司片山 望河村 美穂子
    • C12N15/00
    • C07K14/62G01N33/6893
    • It is intended to provide: a DNA having a promoter region containing a human SGLT homolog regulator sequence; a transformant transformed by the DNA; a method of screening a compound or its salt promoting or inhibiting the human SGLT homolog promoter activity characterized by using the above transformant; a method of screening a drug against diabetes or a drug against hyperlipemia characterized by using the above transformant; a kit for screening a compound or its salt promoting or inhibiting the human SGLT homolog promoter activity characterized by using the above transformant; medicinal compositions containing a compound or its salt promoting or inhibiting the human SGLT homolog promoter activity characterized by using the above transformant which is obtained by using the above-described screening method or screening kit; etc.
    • 旨在提供:具有含有人SGLT同源调节子序列的启动子区的DNA; 由DNA转化的转化体; 筛选化合物或其盐促进或抑制使用上述转化体的人SGLT同源启动子活性的方法; 筛选药物抗糖尿病的方法或抗高脂血症的药物,其特征在于使用上述转化体; 用于筛选化合物或其盐促进或抑制使用上述转化体的人类SGLT同源启动子活性的试剂盒; 含有促进或抑制人SGLT同源启动子活性的化合物或其盐的药物组合物,其特征在于使用上述筛选方法或筛选试剂盒获得的上述转化体; 等等